Celcuity Inc. (CELC) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

Per the Roarable RQD rating, CELC scores 32 out of 100 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are: Fundamental Cash Engine at 6/20 (ROIC -35%; FCF yield -4.53%); Whale 13F Flow at 6/20 (institutional accumulation and options positioning); Insider Conviction at 3/20 (SEC Form 4 and Congressional PTR cluster flow); Macro Regime Fit at 7/20 (Beta 1.0; sector sensitivity); and Forensic Balance Sheet at 10/20 (Altman Z 2.5; Piotroski F 2/9; Debt/Equity 0.5).

Taken together, the lowest-scoring pillars point to weak cash generation and weak insider conviction, the two areas most directly tied to whether the business can self-fund and whether those closest to it are signaling confidence. The highest-scoring pillar, the balance sheet, is only moderate, with a Piotroski F-Score of 2 out of 9 indicating limited financial-strength signals. Per the SEC financials, the company reported negative operating income and negative free cash flow in each of the three listed fiscal years, and the reported cash balance rose from $22.5M to $165.7M over FY 2024 to FY 2025 while FCF was negative in both years. For a prospective investor, the upside case rests on the company's ability to convert its cash position and clinical activity into a sustainable cash engine; the valuation tradeoff is that the market cap of $3.39B is not supported by reported earnings or cash flow in the source data, and the Beta of 1.0 means the stock is expected to move with the broader market rather than independently. This is an analytical framing, not personalized financial advice.

Celcuity Inc. (CELC) is a NASDAQ-listed issuer in the Health Care sector and the Medical Specialities industry, per the profile. The source data does not describe the company's products, customers, or revenue model. The reported revenue in every listed period is $0.0M, per the SEC financials. Not available in source data for the specific product or customer base.

Per the SEC financials, reported revenue was $0.0M in each period and operating losses widened from $-66.2M in FY 2023 to $-172.2M in FY 2025. Gross, operating, and net margins are each listed as 0% in the market data, and ROIC is -35%. The Altman Z-Score is 2.5 and the Piotroski F-Score is 2 out of 9, per the Roarable RQD rating. Debt/Equity is listed as 0.5, while the debt line in the SEC financials is N/A for all periods.

• What products or indications does CELC commercialize, and what is the revenue model behind the reported $0.0M revenue?
• What drove the increase in cash from $22.5M to $165.7M between FY 2024 and FY 2025, and how is the company funding negative free cash flow?
• What is the nature of the debt position, given that debt is listed as N/A while Debt/Equity is 0.5?
• What specific catalysts are referenced in the recent news items, and what is their timing?
• What is the reason for the difference between a 52-week low of $53.54 and a high of $151.02 relative to the current price of $69.3?